dc.contributor.author |
Zaytsev D.V. |
|
dc.contributor.author |
Zaikova E.K. |
|
dc.contributor.author |
Golovkin A.S. |
|
dc.contributor.author |
Bulatov E.R. |
|
dc.contributor.author |
Valiullina A.K. |
|
dc.contributor.author |
Mirgayazova R.M. |
|
dc.contributor.author |
Daks A.A. |
|
dc.contributor.author |
Zaritskey A.Y. |
|
dc.contributor.author |
Petukhov A.V. |
|
dc.date.accessioned |
2021-02-25T20:52:39Z |
|
dc.date.available |
2021-02-25T20:52:39Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
1997-6933 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/162552 |
|
dc.description.abstract |
© 2020 Practical Medicine Publishing House. All rights reserved. Background. Cytokines are considered as important factors that enhance the efficacy of CAR-T cell therapy. Besides, they are key elements of the pathogenesis of cytokine release syndrome and neurotoxicity in applying the CAR-T technology. However, cytokine effects in the context of CAR-T therapy have not yet been properly studied. Aim. To quantitatively assess cytokine secretion using multiplex assay with co-incubation of anti-CD19 CAR-T lymphocytes with epithelial HeLa and A431 cell lines expressing CD19 on their surface. Materials & Methods. T-lymphocytes were transduced with the lentiviral vector containing anti-СD19-CAR gene. CAR expression was tested based on GFP reporter using flow cytometry. To confirm a specific CAR-T cell activation response to tumor antigen, the levels of interleukin-2, interferon-γ, and tumor necrosis factor-α were measured by means of immunoassay. Cytotoxic activity of CAR-T lymphocytes obtained was examined with their direct co-culturing with target cells. The levels of cytokines isolated prior to and after incubation of targets with CAR-T cells were compared using multiplex assay. Results. The level of some proinflammatory cytokines (interleukin-6, interleukin-1β, interferon-γ) (p < 0.01) increased. The difference in the levels of anti-inflammatory cytokines (interleukin-4, interleukin-10) was inconsiderable, and in the HeLa cell line experiment it was insignificant (p > 0.05). The concentration of granulocyte-macrophage colony-stimulating factor (GM-CSF) was many times higher after incubation with CAR-T lymphocytes (p < 0.01). Conclusion. The trial revealed multiple enhancement of GM-CSF, one of the key elements of the pathogenesis of cytokine release syndrome and CAR-T-associated neurotoxicity. The results of further studies of GM-CSF can contribute to improving the efficacy of CAR-T therapy with considerably lower toxicity. |
|
dc.relation.ispartofseries |
Klinicheskaya Onkogematologiya/Clinical Oncohematology |
|
dc.subject |
CAR-T cells |
|
dc.subject |
Cytokines |
|
dc.subject |
GM-CSF |
|
dc.subject |
Immunotherapy |
|
dc.title |
Granulocyte-macrophage colony-stimulating factor and car-t technology for solid tumors in experiment |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
2 |
|
dc.relation.ispartofseries-volume |
13 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
115 |
|
dc.source.id |
SCOPUS19976933-2020-13-2-SID85097267491 |
|